NCT04293276进行中（未招募）2 期
Study to Evaluate the Efficacy and Safety of CDK4/6 Inhibitor SHR6390 Combined With Pyrotinib in the Treatment of HER2-positive Advanced Breast Cancer
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 进行中（未招募）
- 入组人数
- 41
- 试验地点
- 1
- 主要终点
- ORR
研究概览
简要总结
The main purpose of this study was to observe the efficacy and safety of treatment with pyrotinib and CDK4/6 inhibitor SHR6390 for HER2-positive metastatic breast cancer.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Local recurrent or metastatic breast cancer suitable for chemotherapy, confirmed histologically.
- •HER2-positive breast cancer(according to 2018 ASCO/CAP HER2 test guideline).
- •Patients with HER2-positive metastatic breast cancer who had received ≤ 1-line treatment in the past;
- •18-70 years old;
- •ECOG PS 0-1;
- •Life expectancy is not less than 12 weeks;
- •At least one measurable lesion according to RECIST 1.1;
- •ANC ≥ 2.0×10^9/L, PLT ≥ 100×10^9/L, Hb ≥ 90 g/L; TBIL≤1.5ULN; ALT and AST≤3×ULN(ALT and AST≤5×ULN if liver metastasis); BUN and Cr≤1.5×ULN;
- •LVEF ≥ 50% and QTc≤470 ms.
排除标准
- •Patients with symptomatic brain metastasis;
- •Unable to swallow, chronic diarrhea and intestinal obstruction, there are many factors affecting drug use and absorption;
- •patient who received radiotherapy, chemotherapy, surgery (excluding local puncture) or molecular targeted therapy within 4 weeks before admission; those who received anti-tumor endocrine therapy after screening period;
- •Participated in other drug clinical trials within 4 weeks before admission;
- •Tyrosine kinase inhibitors targeting HER2 (Neratinib, Lapatinib, pyrotinib, etc.) have been used or are being used in the past;
- •Other malignant tumors, excluding cured cervical carcinoma in situ, skin basal cell carcinoma or skin squamous cell carcinoma, have been diagnosed in the past five years;
- •A history of immunodeficiency, including HIV positive, HCV, or other acquired, congenital immunodeficiency disorders, or organ transplantation, is known;
- •Has suffered from any heart disease;
- •Female patients during pregnancy and lactation, fertile women with positive baseline pregnancy tests or women of childbearing age who are unwilling to take effective contraceptive measures throughout the trial;
- •According to the judgement of the researchers, there are concomitant diseases that seriously endanger the safety of patients or affect the completion of research (including, but not limited to, severe hypertension, severe diabetes, active infections, etc.);
- •Moderate infection occurs within 4 weeks before the first administration (e.g. intravenous drip of antibiotics, antifungal or antiviral drugs according to clinical criteria), fever(> 38.5 ℃) of unknown origin occurs during the screening period/before the first administration;
- •Researchers believe that patients are not suitable for any other situation in this study.
研究组 & 干预措施
Treatment group
Experimental
Patients with HER2 positive breast cancer will receive Pyrotinib in combination with SHR6390(at protocol defined dose levels) orally until disease progression, unacceptable toxicity, withdrawal of consent or death, whichever occurs first.
干预措施: Pyrotinib (Drug)
Treatment group
Experimental
Patients with HER2 positive breast cancer will receive Pyrotinib in combination with SHR6390(at protocol defined dose levels) orally until disease progression, unacceptable toxicity, withdrawal of consent or death, whichever occurs first.
干预措施: SHR6390 (Drug)
结局指标
主要结局
ORR
时间窗: From the start of treatment to Disease Progress, assessed up to 2 years
ORR by investigator using RECIST Guideline (Version 1.1)
次要结局
- OS(up to 2 years)
- PFS(up to 2 years)
- Adverse Events(from the first drug administration to 30 days from the last dose, assessed up to 2 years)
研究者
研究点 (1)
Loading locations...
相似试验
Unknown
2 期
Study to Evaluate the Efficacy and Safety of CDK4/6 Inhibitor SHR6390 Combined With Pyrotinib in the Treatment of HER2-positive Advanced Breast CancerMetastatic Breast CancerNCT03993964Sun Yat-sen University20
尚未招募
2 期
Pyrotinib Plus Trastuzumab After First-line TH (P) Treatment With HER-2 Positive Breast CancerAdvanced Breast CancerNCT05255523Fujian Medical University Union Hospital60
Unknown
不适用
Real World Study of Pyrotinib in Human Epidermal Growth Factor Receptor-2 (HER2) Positive Breast CancerHER2-positive Breast CancerNCT04158505Chinese Academy of Medical Sciences3,000
招募中
1 期
Phase Ib Clinical Study of KeynatinibLymphoma, B-CellNCT04807881Medolution Ltd.75
已完成
3 期
Efficacy and Safety of Increased Dose of TA-650 (Infliximab) in Patients With Crohn's Disease (CD)Crohn's DiseaseNCT00805766Tanabe Pharma Corporation39